3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Carcinoma, Adenoid Cystic
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
durvalumab
13
Bevacizumab
11
Nivolumab
10
tremelimumab
7
pembrolizumab
6
lenvatinib
6
fludarabine
6
Cyclophosphamide
6
atezolizumab
4
Radiosurgery
4
Cisplatin
4
toripalimab
3
relatlimab
3
Magnetic Resonance Imaging
3
Ipilimumab
3
Gemcitabine
3
X-Rays
2
Standard of Care
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Photons
2
Patient Navigation
2
Lidocaine
2
Hepatectomy
2
Dexamethasone
2
Biopsy
2
trastuzumab deruxtecan
1
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Epirubicin
×
1 year
×
Clear all
No trials found.